Literature DB >> 7341758

Optimal sampling times for pharmacokinetic experiments.

D Z D'Argenio.   

Abstract

A sequential estimation procedure is presented which uses optimal sampling times to estimate the parameters of a model from data obtained from a group of subjects. This optimal sampling sequential estimation procedure utilizes parameter estimates from previous subjects in the group to determine the optimal sampling times for the next subject. Parameter estimates obtained from the optimal sampling procedure are compared to those obtained from a conventional sampling scheme by using Monte Carlo simulations which include noise terms for both assay error and intersubject variability. The results of these numerical experiments, for the two examples considered here, show that the parameter estimates obtained from data collected at optimal sampling times have significantly less variability than those generated using the conventional sampling procedure. We conclude that optimal sampling and preexperiment simulation may be useful tools for designing informative pharmacokinetic experiments.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7341758     DOI: 10.1007/bf01070904

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  12 in total

1.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

Review 2.  Use of statistical methods in evaluation of in vivo performance of dosage forms.

Authors:  W J Westlake
Journal:  J Pharm Sci       Date:  1973-10       Impact factor: 3.534

3.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

4.  Problems associated with analysis of pharmacokinetic models.

Authors:  W J Westlake
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

5.  Disposition kinetics of lidocaine in normal subjects.

Authors:  M Rowland; P D Thomson; A Guichard; K L Melmon
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

6.  Investigation of the effect of data error in the analysis of biological tracer data from three compartment systems.

Authors:  J Myhill
Journal:  J Theor Biol       Date:  1969-05       Impact factor: 2.691

7.  A priori lithium dosage regimen using population characteristics of pharmacokinetic parameters.

Authors:  J Gaillot; J L Steimer; A J Mallet; J J Thebault; A Bieder
Journal:  J Pharmacokinet Biopharm       Date:  1979-12

8.  Pharmacokinetics--uses and abuses.

Authors:  P J Fell; M T Stevens
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

9.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

10.  Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.

Authors:  J J Lima; D R Conti; A L Goldfarb; W J Tilstone; L H Golden; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1979-02
View more
  86 in total

1.  Construction of an optimal destructive sampling design for noncompartmental AUC estimation.

Authors:  F Vandenhende; M Comblain; M H Delsemme; W Dewe; W P Hoffman; B Boulanger
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

2.  Robust optimal design for the estimation of hyperparameters in population pharmacokinetics.

Authors:  M Tod; F Mentré; Y Merlé; A Mallet
Journal:  J Pharmacokinet Biopharm       Date:  1998-12

3.  Pharmacokinetics of isepamicin during continuous venovenous hemodiafiltration.

Authors:  D Breilh; B Allaouchiche; H Jaumain; P Boulétreau; D Chassard; I Malbec; D Ducint; M C Saux
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Optimal experimental design for precise estimation of the parameters of the axial dispersion model of hepatic elimination.

Authors:  C H Chou; L Aarons; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1998-10

Review 5.  Pharmacokinetically guided administration of chemotherapeutic agents.

Authors:  H J van den Bongard; R A Mathôt; J H Beijnen; J H Schellens
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

6.  An extended point-area deconvolution approach for assessing drug input rates.

Authors:  K C Yeh; D J Holder; G A Winchell; L A Wenning; T Prueksaritanont
Journal:  Pharm Res       Date:  2001-10       Impact factor: 4.200

7.  Optimal design of a population pharmacodynamic experiment for ivabradine.

Authors:  S B Duffull; F Mentré; L Aarons
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

8.  Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).

Authors:  Charlotte van Kesteren; R A A Mathôt; E Raymond; J P Armand; P Fumoleau; C Punt; M Ravic; J Wanders; J H Beijnen; J H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 9.  Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Authors:  Ch van Kesteren; R A A Mathôt; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

10.  Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children.

Authors:  M Philippe; S Goutelle; J Guitton; X Fonrose; C Bergeron; P Girard; Y Bertrand; N Bleyzac
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.